Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613086 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL4813600 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL2987235 | 0.81 | HTT (0.53) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL3617440 | 0.79 | HTT (0.50) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL3617442 | 0.79 | HTT (0.50) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL7715181 | 0.78 | ALDH1A1 (0.67) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL5325708 | 0.78 | ALDH1A1 (0.67) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL8358191 | 0.78 | ALDH1A1 (0.67) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL7385780 | 0.78 | ALDH1A1 (0.67) | ALDH1A1TSHRHTTKMT2AMEN1 | |
| SCHEMBL7769347 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20130281523-A1 | LOW DOSE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2013-10-24 | — | — | US | disclosed |
| EP-2640379-A2 | LOW DOSE CANNABINOID MEDICAMENTS | Pier Pharmaceuticals (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20120231083-A1 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012068516-A2 | LOW DOSE CANNABINOID MEDICAMENTS | PIER PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-8178496-B2 | Photoreactive regulator of glutamate receptor function and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20030050224-A1 | Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord | NEDERGAARD MAIKEN (US) | 2003-03-13 | — | — | US | disclosed |
| WO-2003015713-A2 | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS | NEDERGAARD MAIKEN (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | disclosed |
| US-5767130-A | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists | OLNEY JOHN W (US) | 1998-06-16 | — | — | US | disclosed |